B+
Bull case
20%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
SLDB
Solid BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$5.20
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-17
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+44.8
Score
AI commentary
The latest substantive company operating update located was the August 6 release; the October 1 release concerned inducement grants, not new clinical results. No verified 30-day news score, social score, options skew, short-interest figure, employee score or recent analyst revisions were supplied, so the zero sentiment fields above denote unavailable data, not neutral measurements. The deterministic directional prior remains negative despite stronger primary-source coverage. Solid press-release list
RankAlpha Sentiment Codex - 2026-10-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventSGT-003 FDA discussionHigh impact
Solid plans a late-Q4 2026 FDA meeting to discuss its INSPIRE DUCHENNE data package and seek guidance on a potential accelerated-approval pathway. The outcome, not the meeting itself, is the key valuation test; no accelerated pathway has been granted. [#PR-EARNINGS-2026-08-06] [#IR-2026-08-06]
2026-12-31eventSGT-501 first dosingMedium impact
Solid expects to dose the first participant in its Phase 1b ARTEMIS trial in H2 2026, subject to enrollment. This would establish clinical execution, but initial safety data are not expected until H1 2027. [#IR-2026-08-06]
2027-03-31catalystInitial SGT-212 FALCON dataHigh impact
Solid expects initial Phase 1b FALCON data in Q1 2027, subject to enrollment. Only two participants had been dosed as of August 4, 2026, limiting confidence in the timing and readout. [#PR-EARNINGS-2026-08-06] [#IR-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-17 • Updated nightlySource: Internal modelMethodology